U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C12H20NO8S.Zn
Molecular Weight 742.117
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOPIRAMATE ZINC

SMILES

[Zn++].[H][C@@]12CO[C@@]3(COS([NH-])(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2.[H][C@@]45CO[C@@]6(COS([NH-])(=O)=O)OC(C)(C)O[C@@]6([H])[C@]4([H])OC(C)(C)O5

InChI

InChIKey=UFUVRSLZPOUTGZ-RZTSBURASA-N
InChI=1S/2C12H20NO8S.Zn/c2*1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12;/h2*7-9H,5-6H2,1-4H3,(H-,13,14,15);/q2*-1;+2/t2*7-,8-,9+,12+;/m11./s1

HIDE SMILES / InChI
Molecular Formula C12H21NO8S
Molecular Weight 339.362
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf

Topiramate is an anticonvulsant indicated in the treatment of epilepsy and migraine. Topiramate enhances GABA-activated chloride channels. In addition, topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. There is evidence that topiramate has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particular subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages. Topiramate inhibits maximal electroshock and pentylenetetrazol-induced seizures as well as partial and secundarily generalized tonic-clonic seizures in the kindling model, findings predective of a broad spectrum of antiseizure activities clinically. The precise mechanism of action of topiramate is not known. However, studies have shown that topiramate blocks the action potentials elicited repetitively by a sustained depolarization of the neurons in a time-dependent manner, suggesting a state-dependent sodium channel blocking action. Topiramate also augments the activity of the neurotransmitter gamma-aminobutyrate (GABA) at some subtypes of the GABAAreceptor (controls an integral chloride channel), indicating a possible mechanism through potentiation of the activity of GABA. Topiramate also demonstrates antagonism of the AMPA/kainate subtype of the glutamate excitatory amino acid receptor. It also inhibits carbonic anhydrase (particularly isozymes II and IV), but this action is weak and unlikely to be related to its anticonvulsant actions. Topiramate is used for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. Topiramate is sold under the brand name Topamax. A combination product containing phentermine and topiramate extended-release called QSYMIA® is indicated for the management of obesity.

CNS Activity

Originator

Approval Year

1996
225
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 5.0 nM [Ki]
Inhibitor
8297
 4.9 µM [Ki]
Inhibitor
8297
 0.9 nM [Ki]
Inhibitor
8297
 3.8 nM [Ki]
Agonist
2678
Inhibitor
8297
 63.0 nM [Ki]
Inhibitor
8297
 30.0 nM [Ki]
Inhibitor
8297
 47.0 nM [Ki]
Inhibitor
8297
Positive Allosteric Modulator
179
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
TOPAMAX

Approved Use

TOPAMAX is indicated for: Monotherapy epilepsy: Initial monotherapy in patients > 2 years of age with partial onset or primary generalized tonic-clonic seizures Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients >2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) Migraine: Treatment for adults and adolescents 12 years of age and older for prophylaxis of migraine headache

Launch Date

1996
Preventing
Approved
8429
TOPAMAX

Approved Use

TOPAMAX is indicated for: Monotherapy epilepsy: Initial monotherapy in patients > 2 years of age with partial onset or primary generalized tonic-clonic seizures Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients >2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) Migraine: Treatment for adults and adolescents 12 years of age and older for prophylaxis of migraine headache

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.98 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
8 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.46 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
1.63 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.38 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
28.73 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.68 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
350.3 mg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
311.2 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
57.3 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
59.8 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
22 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
20 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
23 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8930774
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
59%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unknown, unknown
 TOPIRAMATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg 1 times / day steady, oral
MTD
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24861853
healthy, 23.3 years (range: 20–26 years)
n = 8
Health Status: healthy
Age Group: 23.3 years (range: 20–26 years)
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/24861853
Sources:
https://pubmed.ncbi.nlm.nih.gov/24861853
4000 mg single, oral
Overdose
Dose: 4000 mg
Route: oral
Route: single
Dose: 4000 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19514879
unknown, 24 years
n = 1
Health Status: unknown
Age Group: 24 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19514879
Sources:
https://pubmed.ncbi.nlm.nih.gov/19514879
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Disc. AE: Attention concentration difficulty, Fever...
AEs leading to
discontinuation/dose reduction:
Attention concentration difficulty (>=2)
Fever (>=2)
Flushing (>=2)
Confusion (>=2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Disc. AE: Memory impairment, Fatigue...
AEs leading to
discontinuation/dose reduction:
Memory impairment (>=2)
Fatigue (>=2)
Asthenia (>=2)
Insomnia (>=2)
Somnolence (>=2)
Paresthesia (>=2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Disc. AE: Psychomotor retardation, Memory impairment...
AEs leading to
discontinuation/dose reduction:
Psychomotor retardation (4%)
Memory impairment (3.2%)
Fatigue (3.2%)
Confusion (3.1%)
Somnolence (3.2%)
Attention concentration difficulty (2.9%)
Anorexia (2.7%)
Depression (2.6%)
Dizziness (2.5%)
Weight decrease (2.5%)
Nervousness (2.3%)
Ataxia (2.1%)
Paresthesia (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
Disc. AE: Convulsions aggravated, Attention concentration difficulty...
AEs leading to
discontinuation/dose reduction:
Convulsions aggravated (2.3%)
Attention concentration difficulty (1.6%)
Language disorder (1.3%)
Personality disorder (1.3%)
Somnolence (1.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
96 g single, oral
Overdose
Dose: 96 g
Route: oral
Route: single
Dose: 96 g
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Other AEs: Coma...
Other AEs:
Coma (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Attention concentration difficulty >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Confusion >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Fever >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Flushing >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Asthenia >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Fatigue >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Insomnia >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Memory impairment >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Paresthesia >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Somnolence >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Paresthesia 2%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Ataxia 2.1%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Nervousness 2.3%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Dizziness 2.5%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Weight decrease 2.5%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Depression 2.6%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Anorexia 2.7%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Attention concentration difficulty 2.9%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Confusion 3.1%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Fatigue 3.2%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Memory impairment 3.2%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Somnolence 3.2%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Psychomotor retardation 4%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/24861853
Language disorder 1.3%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
Personality disorder 1.3%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
Somnolence 1.3%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
Attention concentration difficulty 1.6%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
Convulsions aggravated 2.3%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf
Coma 1 patient
96 g single, oral
Overdose
Dose: 96 g
Route: oral
Route: single
Dose: 96 g
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:63631
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63631
ChemicalBook
CB7402630
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7402630
MolPort
MolPort-001-615-062
https://www.molport.com/shop/molecule-link/MolPort-001-615-062
Selleck Chemicals
Topiramate
http://www.selleckchem.com/products/Topiramate.html
ZINC
ZINC000095616603
http://zinc15.docking.org/substances/ZINC000095616603
eMolecules
29547217
https://www.emolecules.com/cgi-bin/more?vid=29547217
eMolecules
29548990
https://www.emolecules.com/cgi-bin/more?vid=29548990
eMolecules
594585
https://www.emolecules.com/cgi-bin/more?vid=594585
PubMed

PubMed

TitleDatePubMed
Developments in mood stabilisers.
2001
Cutaneous drug reaction case reports: from the world literature.
2001
Comparative efficacy and tolerability of drug treatments for bipolar disorder.
2001
Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy.
2001
Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications.
2001
The management of refractory idiopathic epilepsies.
2001
Management strategies for refractory localization-related seizures.
2001
Topiramate in posttraumatic stress disorder: preliminary clinical observations.
2001
The new generation of GABA enhancers. Potential in the treatment of epilepsy.
2001
Cognitive side effects of anticonvulsants.
2001
Auditory hallucinations associated with topiramate.
2001 Aug
Confusion and dysphoria with low-dose topiramate in a patient with bipolar disorder.
2001 Aug
Newer antiepileptic drugs: advantages and disadvantages.
2001 Aug
Uveal effusion and secondary angle-closure glaucoma associated with topiramate use.
2001 Aug
First break of mania associated with topiramate treatment.
2001 Aug
Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction.
2001 Aug
Panic attacks associated with the use of topiramate.
2001 Aug
Intrinsic optical signals and electrographic seizures in the rat limbic system.
2001 Dec
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy.
2001 Dec
Topiramate selectively attenuates nicotine-induced increases in monoamine release.
2001 Dec 1
Effect of tiagabine and topiramate on porphyrin metabolism in an in vivo model of porphyria.
2001 Jul
The role of new antiepileptic drugs.
2001 Jul
Incoercible topiramate-related vomiting in a patient with epilepsy and mental retardation.
2001 Jun
Topiramate for self-mutilation in a patient with borderline personality disorder.
2001 Jun
Topiramate abuse in a bipolar patient with an eating disorder.
2001 Jun
Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design.
2001 Jun
[Social and economic aspects of administration of new antiepileptic drugs].
2001 Mar-Apr
Clinical experience with topiramate dosing and serum levels in children 12 years or under with epilepsy.
2001 Nov
Bilateral angle-closure glaucoma and ciliary body swelling from topiramate.
2001 Nov
National survey on West syndrome in Korea.
2001 Nov
Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation.
2001 Nov
Hypohidrosis related to the administration of topiramate to children.
2001 Oct
Topiramate-induced metabolic acidosis: report of two cases.
2001 Oct
Plasma concentration of topiramate correlates with cerebrospinal fluid concentration.
2001 Oct
Quetiapine-related tardive dyskinesia.
2001 Oct
Topiramate-induced depression.
2001 Oct
Drug-resistant cluster headache responding to gabapentin: a pilot study.
2001 Sep
[Topiramate: an experience in children with partial epilepsy].
2001 Sep
Re: Weight change with antipsychotic use.
2001 Sep
Postmarketing experience with topiramate and cognition.
2001 Sep
Topiramate for headaches.
2001 Sep
Weight loss with topiramate.
2001 Sep
Topiramate blocks perinatal hypoxia-induced seizures in rat pups.
2001 Sep
Topiramate as a mood stabilizer.
2001 Sep
Topiramate on ictal seizure semiology: a quantitative, randomized, low and medium dose-controlled study.
2001 Sep
Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma.
2001 Sep 15
Topiramate as a neuroprotectant in a rat model of global ischemia-induced neurodegeneration.
2001 Sep 28
Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.
2001 Sep-Oct
Clinical and electroencephalographic effects of topiramate in patients with epilepsy and healthy volunteers.
2001 Sep-Oct
Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder.
2001 Sep-Oct
Patents

Patents

JP2002541106A
98
JP2008513466A
22
JP2011526889A
16

Sample Use Guides

In Vivo Use Guide
Recommended dose: 400 mg orally per day in 2 divided doses of 200 mg each The dose should be achieved by titration: Week 1: 25 mg orally in the morning and 25 mg orally in the evening Week 2: 50 mg orally in the morning and 50 mg orally in the evening Week 3: 75 mg orally in the morning and 75 mg orally in the evening Week 4: 100 mg orally in the morning and 100 mg orally in the evening Week 5: 150 mg orally in the morning and 150 mg orally in the evening Week 6: 200 mg orally in the morning and 200 mg orally in the evening
Route of Administration: Oral
In Vitro Use Guide
0.3 to 10 uM topiramate 1 inhibited ATPA-evoked postsynaptic currents recorded from rat basolateral amygdala (BLA) interneurons
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:06:30 GMT 2023
Edited
by admin
on Sat Dec 16 08:06:30 GMT 2023
Record UNII
Q54IQZ256J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOPIRAMATE ZINC
Common Name English
.BETA.-D-FRUCTOPYRANOSE, 2,3:4,5-BIS-O-(1-METHYLETHYLIDENE)-, 1-SULFAMATE, ZINC SALT (2:1)
Systematic Name English
(-)-TOPIRAMATE ZINC
Common Name English
ZINC TOPIRAMATE
Common Name English
Code System Code Type Description
CAS
1246279-02-6
Created by admin on Sat Dec 16 08:06:30 GMT 2023 , Edited by admin on Sat Dec 16 08:06:30 GMT 2023
PRIMARY
PUBCHEM
72942004
Created by admin on Sat Dec 16 08:06:30 GMT 2023 , Edited by admin on Sat Dec 16 08:06:30 GMT 2023
PRIMARY
FDA UNII
Q54IQZ256J
Created by admin on Sat Dec 16 08:06:30 GMT 2023 , Edited by admin on Sat Dec 16 08:06:30 GMT 2023
PRIMARY
Related Record Type Details
Structure of TOPIRAMATE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966